EIF2A and myeloid sarcoma: Post-mortem tissue analysis revealed that AD, PD, and MS patients display increased levels of UPR markers including CHOP, BiP, pPERK, p-eIF2α, pIRE1, and XBP1 (Hoozemans et al., 2007, 2009; Mháille et al., 2008; Wheeler et al., 2019).